1. CYP4F2 genetic variant alters required warfarin dose
by Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y. Langaee, Charles Eby, Cristi R. King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H. Yale, Kai Qi Zhang, Richard L. Berg, and James K. Burmester
Blood
Volume 111(8):
April 15, 2008
©2008 by American Society of Hematology

2. Depiction of relative statistical relationships of SNPs with predicted warfarin therapeutic dose, Marshfield model.
Depiction of relative statistical relationships of SNPs with predicted warfarin therapeutic dose, Marshfield model. The P value (log scale) for each polymorphism, comparing residuals for warfarin dose, was plotted. Dashed line shows the adjusted threshold for significance.
Michael D. Caldwell et al. Blood 2008;111:
©2008 by American Society of Hematology

3. Warfarin therapeutic dose by CYP4F2 genotype and study site.
Warfarin therapeutic dose by CYP4F2 genotype and study site. Box plots of dose by study site and CYP4F2 (all cases). Boxes extend from the 25th to the 75th percentiles, with a horizontal line at the median and vertical lines extending to the 10th and 90th percentiles.
Michael D. Caldwell et al. Blood 2008;111:
©2008 by American Society of Hematology

4. Marshfield model residuals by CYP4F2 genotype and study site (
Marshfield model residuals by CYP4F2 genotype and study site (*1 genotypes only).
Marshfield model residuals by CYP4F2 genotype and study site (*1 genotypes only). Model adjusts for age, gender, body surface area, indication for warfarin, VKORC1, and CYP2C9. Boxes extend from the 25th to the 75th percentiles, with a horizontal line at the median and vertical lines extending to the 10th and 90th percentiles.
Michael D. Caldwell et al. Blood 2008;111:
©2008 by American Society of Hematology